Vertex Pharmaceuticals (VRTX) PEG Ratio: History & Chart

Vertex Pharmaceuticals Incorporated(VRTX)

Biotechnology · Boston, MA

$521.68-7.22 (-1.37%)

Delayed quote: Sep 9, 2026, 11:10 AM EDT

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA

6,400 employees

www.vrtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Reshma Kewalramani

View full financials

VRTX PEG Ratio Metrics

PEG RATIO

3.77

PEG RATIO AVG TTM

2.58

PEG RATIO AVG 3Y

1.90

PEG RATIO AVG 5Y

1.47

PEG RATIO AVG 10Y

1.43

PEG RATIO AVG 15Y

1.27

PEG RATIO AVG 20Y

1.15

CURRENT VS TTM AVG

+45.84%

CURRENT VS 3Y AVG

+98.77%

CURRENT VS 5Y AVG

+156.90%

CURRENT VS 10Y AVG

+164.43%

CURRENT VS 15Y AVG

+196.85%

CURRENT VS 20Y AVG

+228.11%

SECTOR MEDIAN · HEALTHCARE

1.81

median of 59 covered companies

CURRENT VS SECTOR MEDIAN

+108.29%

vs the sector median at left

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Vertex Pharmaceuticals Incorporated (VRTX)	$132.40B	3.77	2.58	1.90	1.47
Bristol-Myers Squibb Company (BMY)vs ›	$131.47B	1.52	0.24	0.24	0.18
Intuitive Surgical, Inc. (ISRG)vs ›	$124.04B	3.17	3.02	2.60	2.27
Danaher Corporation (DHR)vs ›	$143.51B	91.13	1.24	1.13	1.93
CVS Health Corp. (CVS)vs ›	$121.03B	N/A	0.13	1.20	1.17
Medtronic plc (MDT)vs ›	$118.61B	6.72	3.73	3.73	2.72
Pfizer Inc. (PFE)vs ›	$158.73B	N/A	0.07	0.13	0.16
McKesson Corporation (MCK)vs ›	$104.60B	0.46	1.11	0.76	0.58
Stryker Corporation (SYK)vs ›	$104.54B	5.16	5.16	2.81	2.63
Sanofi (SNY)vs ›	$103.14B	0.28	5.85	4.07	3.06

NAME

MARKET CAP

PEG RATIO

TTM

Vertex Pharmaceuticals Incorporated (VRTX)

$132.40B

3.77

2.58

1.90

1.47

Bristol-Myers Squibb Company (BMY)vs ›

$131.47B

1.52

0.24

0.18

Intuitive Surgical, Inc. (ISRG)vs ›

$124.04B

3.17

3.02

2.60

2.27

Danaher Corporation (DHR)vs ›

$143.51B

91.13

1.24

1.13

1.93

CVS Health Corp. (CVS)vs ›

$121.03B

N/A

0.13

1.20

1.17

Medtronic plc (MDT)vs ›

$118.61B

6.72

3.73

2.72

Pfizer Inc. (PFE)vs ›

$158.73B

N/A

0.07

0.13

0.16

McKesson Corporation (MCK)vs ›

$104.60B

0.46

1.11

0.76

0.58

Stryker Corporation (SYK)vs ›

$104.54B

5.16

2.81

2.63

Sanofi (SNY)vs ›

$103.14B

0.28

5.85

4.07

3.06

PEG Ratio FAQ

What is the PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The PEG ratio for VRTX stock is 3.77.

Is Vertex Pharmaceuticals Incorporated's PEG ratio high or low?

The PEG ratio of 3.77 is 157% above its 4-year average of 1.47, near the high end of its 4-year range (0.18–3.77).

What is the TTM average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The TTM average PEG ratio for VRTX stock is 2.58.

What is the 3Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 3Y average PEG ratio for VRTX stock is 1.90.

What is the 5Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 5Y average PEG ratio for VRTX stock is 1.47.

What is the 10Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 10Y average PEG ratio for VRTX stock is 1.43.

What is the 15Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 15Y average PEG ratio for VRTX stock is 1.27.

What is the 20Y average PEG ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 20Y average PEG ratio for VRTX stock is 1.15.

DATE	PEG RATIO
2024-12-31	1.69
2023-12-31	3.48
2022-12-31	0.52
2020-12-31	0.18
2018-12-31	0.03
2016-12-31	2.00
2015-12-31	2.08
2012-12-31	0.18
2006-12-31	1.04
2004-12-31	0.29
2000-12-31	4.62
1997-12-31	0.65

DATE

PEG RATIO

2024-12-31

1.69

2023-12-31

3.48

2022-12-31

0.52

2020-12-31

0.18

2018-12-31

0.03

2016-12-31

2.00

2015-12-31

2.08

2012-12-31

0.18

2006-12-31

1.04

2004-12-31

0.29

2000-12-31

4.62

1997-12-31

0.65

PEG Ratio: 3.77

VRTX PEG Ratio Chart

VRTX Average PEG Ratio Chart

VRTX Current vs Average PEG Ratio Chart

VRTX PEG Ratio Metrics

VRTX Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

PEG Ratio FAQ

VRTX PEG Ratio History

Related Metrics